Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02153632 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID
A Phase 3 study, sponsored by Adamas Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 135
- Enrollment target
NCT02153632 is a Phase 3 study that was terminated before completion, run by Adamas Pharmaceuticals. The registered enrollment target is 135 participants.
The verdict
NCT02153632, a Phase 3 study, was terminated before completion, sponsored by Adamas Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 135 participants
- Enrollment target
Study Summary
The purpose of this multi-center, randomized, double-blind, parallel-group, 26 week study is to compare the efficacy and safety of two different dose levels of Amantadine Extended Release Tablets to placebo for the treatment of levodopa induced dyskinesia in patients with Parkinson's disease.
Interventions
- DRUG Placebo
- DRUG amantadine HCl ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2014-07-30 |
| Est. Completion | 2016-05-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02153632
The ClinicalTrials.gov registry entry for NCT02153632 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adamas Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02153632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02153632 about?
NCT02153632 is a clinical study titled "Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID". The purpose of this multi-center, randomized, double-blind, parallel-group, 26 week study is to compare the efficacy and safety of two different dose levels of Amantadine Extended Release Tablets to placebo for the treatment of levodopa induced dyskinesia in patients with Parkinson's disease.
What is the current status of trial NCT02153632?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 135 participants. The study started on 2014-07-30. Estimated completion is 2016-05-20.
What interventions are being tested in trial NCT02153632?
The interventions under investigation include: Placebo (DRUG), amantadine HCl ER (DRUG).
Who is sponsoring clinical trial NCT02153632?
This trial is sponsored by Adamas Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.